This Biotech Company Could Be the Site of A Zombie Breakthrough

In your favorite movies and TV series, when a major character dies, you know somehow that there is still a chance that the character could return in a future installment or later season. But that kind of thing only happens  onscreen. In real life, once you die, the game is over, no restart button, no reload points.

However, Bioquark Inc, a Philadelphia-based biotech company claims that bringing the dead back to life is still highly possible using modern technology.

"With the convergence of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation, we are poised to delve into an area of scientific understanding previously inaccessible with existing technologies," said Ira Pastor, CEO of Bioquark, in a statement.

After being approved by the American and Indian institutional review boards, Bioquark, together with its partner Revita Life, is set to conduct a first of its kind trial in hopes to have a better understanding on how to reverse death.

Their first trial will involve 20 patients that are declared to be clinically dead, or brain dead, that are being kept alive by life support.

During the first stage of the trial, the patients will receive weekly peptide injections directly into their spinal cords, along with biweekly stem cell treatments, New York Daily News reported.

In addition to peptides, researchers will also utilize stem cell injections into the brain, lasers and nerve stimulation techniques that have worked to awaken comatose patients.

The patients are then put under strict observation for about six months. Signs of regeneration in the upper spinal cord will be monitored using brain imaging equipment. The upper spinal cord is the one responsible for the controls in breathing and heartbeat.

"Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative CNS conditions, including Alzheimer's and Parkinson's disease," said Dr. Sergei Paylian, Founder, President, and Chief Science Officer of Bioquark Inc.